Loading...

Intellectia LogoIntellectia
AI Trading Bot
Features
Markets
News
Resources
Pricing
Get Started
  1. Home
  2. Stock
  3. TCRT
TCRT logo

TCRT Overview

-
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
OverviewStock Price PredictionTechnicalValuationFinancialsEarningsShould I BuyNews & Events
an image of Intellectia Logoan image of Intellectia

Most Trusted AI Platform for Winning Trades

TwitterYoutubeQuoraDiscordLinkedinTelegram

Copyright © 2026 Intellectia.AI. All Rights Reserved.

Company

  • Home
  • Contact
  • About Us
  • Press
  • Privacy
  • Terms of Service
  • Service Terms of Use

Resources

  • Blog
  • Tutorial
  • Help Center
  • Affiliate Program

Markets

  • Market Analysis
  • Crypto
  • Featured Screeners
  • AI Earnings Calendar
  • Market Movers
  • Stock Monitor
  • Economic Calendar
  • All US Stocks
  • All Cryptos

Tools

  • Dividend Calculator
  • Dividend Yield Calculator
  • Options Profit Calculator

Features

  • QuantAI Alpha Pick
  • SwingMax Portfolio
  • Swing Trading
  • AI Stock Picker
  • Whales Auto Tracker
  • Daytrading Center
  • Patterns Detection
  • AI Screener
  • Financial AI Agent
  • Backtesting Playground
  • AI Earnings Prediction
  • Stock Monitor
  • Technical Analysis

News

  • Overview
  • Top News
  • Daily Market Brief
  • Earnings Analysis
  • Newswire
  • Stock News
  • Crypto News
  • Institution News
  • Congress News
  • Monitor News

Compare

  • TradingView
  • SeekingAlpha
Intellectia

Loading chart...

High
3.045
Open
2.970
VWAP
2.99
Vol
10.48K
Mkt Cap
6.65M
Low
2.930
Amount
31.27K
EV/EBITDA(TTM)
--
Total Shares
2.23M
EV
4.71M
EV/OCF(TTM)
--
P/S(TTM)
876.85
Alaunos Therapeutics, Inc. is a pre-clinical obesity and metabolic disorder and clinical-stage oncology-focused cell therapy company. The Company focuses on developing small molecules that are expected to be efficacious against obesity and other metabolic disorders. The Company is engaged in developing novel small molecule-based obesity therapeutics. The Company’s operations consist primarily of conducting research and development and raising capital to fund those efforts. The Company has not generated any revenues.
Show More

Events Timeline

(ET)
2026-03-02
06:40:00
Alaunos Therapeutics Releases Early Data on ALN1003
select
2025-06-23 (ET)
2025-06-23
08:05:06
Alaunos prices 610,399 shares at $3.36 in registered direct offering
select

News

Benzinga
9.0
03-02Benzinga
Alaunos Therapeutics Reveals Promising ALN1003 Preclinical Data
  • Significant Drug Effects: Alaunos Therapeutics' ALN1003 demonstrated a mean weight loss of up to -12.9% in diet-induced obesity mouse studies, indicating potential as a new treatment option for obesity.
  • Liver Health Improvement: The drug reduced liver weight by 43% compared to untreated mice, highlighting its effectiveness and potential to lower the risk of obesity-related liver diseases.
  • Biochemical Indicator Improvement: Long-term administration of ALN1003 was associated with significant reductions in ALT, AST, and ALP levels, along with a trend toward lower total bilirubin, suggesting its potential in improving metabolic health.
  • Future Development Plans: The company plans to pursue additional financing to support ongoing preclinical work for ALN1003 and optimize manufacturing processes, ensuring drug efficacy and safety to pave the way for future IND applications.
Newsfilter
9.0
03-02Newsfilter
Alaunos' ALN1003 Drug Candidate Shows Weight Loss Potential
  • Significant Weight Loss: In the DIO mouse model, ALN1003-treated mice exhibited an average weight reduction of -12.9%, indicating the drug's potential efficacy in obesity treatment.
  • Liver Health Improvement: ALN1003 reduced liver weight by 43% and lowered liver injury biomarkers such as ALT and AST, suggesting a positive impact on metabolic-associated liver disease.
  • Reduced Food and Water Intake: The ALN1003 treatment group consumed significantly less food (347.5g/cage vs 425.0g/cage), which may correlate with the drug's weight loss mechanism, further supporting its potential as a non-hormonal treatment.
  • Ongoing R&D Plans: Alaunos is focused on conducting additional preclinical studies and optimizing manufacturing processes to advance ALN1003, aiming to provide a new non-hormonal treatment option for obesity patients.
Benzinga
2.0
2025-09-03Benzinga
4 Biotech Stocks Experiencing Decline: Momentum Scores Diminishing in the Last Week
  • Biotech Stocks Momentum Decline: Several biotech stocks have experienced significant declines in their Momentum scores over the past week, indicating a loss of strength in the sector.

  • Key Companies Affected: Notable companies like Capricor Therapeutics, Lava Therapeutics, Alaunos Therapeutics, and Champions Oncology have all reported drops in their Momentum scores due to various factors, including regulatory setbacks, financial losses, and downgrades from analysts.

Globenewswire
8.5
2025-06-18Globenewswire
PMGC Capital LLC Urges Alaunos Therapeutics (NASDAQ: TCRT) to Accept Term Sheet from Leading Wall Street Bank Behind Many Leading Crypto Strategies
  • PMGC Capital's Urging of Alaunos Therapeutics: PMGC Capital LLC has publicly urged Alaunos Therapeutics to accept a financing term sheet facilitated by a leading Wall Street bank, emphasizing that it represents a significant opportunity for the company and its shareholders.

  • Commitment to Shareholder Value: PMGC Capital remains dedicated to collaborating with Alaunos' leadership to enhance long-term shareholder value while commending the company's prudent financial management during challenging market conditions.

Newsfilter
8.5
2025-05-14Newsfilter
PMGC Capital LLC, a Subsidiary of PMGC Holdings Inc. (Nasdaq: ELAB), To File Schedule 13D Reporting 5.09% Stake in Alaunos Therapeutics, Inc. (Nasdaq: TCRT)
  • PMGC Capital's Acquisition: PMGC Capital LLC announced its acquisition of 83,500 shares (approximately 5.09%) in Alaunos Therapeutics, indicating a belief that the company is undervalued and has potential for growth.

  • Strategic Engagement Plans: PMGC Capital intends to engage with Alaunos' management to explore strategic opportunities such as mergers, acquisitions, or partnerships, while commending Alaunos for its financial stewardship.

Business Insider
9.5
2024-08-16Business Insider
TCRT Stock Earnings: Alaunos Therapeutics Reported Results for Q2 2024
  • Earnings Report: Alaunos Therapeutics reported a second quarter 2024 earnings per share of -71 cents and revenue of $4,000.

  • Automated Coverage: InvestorPlace Earnings utilizes TradeSmith data to automate the reporting of quarterly earnings, providing quick access to key financial figures without human intervention.

Valuation Metrics

The current forward P/E ratio for Alaunos Therapeutics Inc (TCRT.O) is -0.08, compared to its 5-year average forward P/E of -3.16. For a more detailed relative valuation and DCF analysis to assess Alaunos Therapeutics Inc's fair value, Click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
-3.16
Current PE
-0.08
Overvalued PE
-0.81
Undervalued PE
-5.51

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
0.01
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
0.34
Undervalued EV/EBITDA
-0.32

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
3421.07
Current PS
0.00
Overvalued PS
13403.85
Undervalued PS
-6561.71

Financials

AI Analysis
Annual
Quarterly

Related Community Screener

create swing trade setup
Intellectia · 358 candidates
Price: $1.00 - $5.00List Exchange: XNAS, XNYS, XASEMoving Average Relationship: PriceAboveMA20, PriceBelowMA5, PriceBelowMA10Week Price Change Pct: $-10.00 - $10.00Macd: bullish, positive
Ticker
Name
Market Cap$
top bottom
TCRT logo
TCRT
Alaunos Therapeutics Inc
7.60M
OSTX logo
OSTX
OS Therapies Inc
53.17M
NNOX logo
NNOX
Nano-X Imaging Ltd
169.34M
FLNT logo
FLNT
Fluent Inc
107.58M
LXRX logo
LXRX
Lexicon Pharmaceuticals Inc
685.30M
MRT logo
MRT
Marti Technologies Inc
175.91M

Whales Holding TCRT

Trading Trends

    Insider
    Hedge Fund
    Congress Trading

People Also Watch

Frequently Asked Questions

What is Alaunos Therapeutics Inc (TCRT) stock price today?

The current price of TCRT is 2.98 USD — it has decreased -1

What is Alaunos Therapeutics Inc (TCRT)'s business?

Alaunos Therapeutics, Inc. is a pre-clinical obesity and metabolic disorder and clinical-stage oncology-focused cell therapy company. The Company focuses on developing small molecules that are expected to be efficacious against obesity and other metabolic disorders. The Company is engaged in developing novel small molecule-based obesity therapeutics. The Company’s operations consist primarily of conducting research and development and raising capital to fund those efforts. The Company has not generated any revenues.

What is the price predicton of TCRT Stock?

Wall Street analysts forecast TCRT stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for TCRT is USD with a low forecast of USD and a high forecast of USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

What is Alaunos Therapeutics Inc (TCRT)'s revenue for the last quarter?

Alaunos Therapeutics Inc revenue for the last quarter amounts to 0.00 USD, decreased

What is Alaunos Therapeutics Inc (TCRT)'s earnings per share (EPS) for the last quarter?

Alaunos Therapeutics Inc. EPS for the last quarter amounts to -0.53 USD, decreased -24.29

How many employees does Alaunos Therapeutics Inc (TCRT). have?

Alaunos Therapeutics Inc (TCRT) has 1 emplpoyees as of March 30 2026.

What is Alaunos Therapeutics Inc (TCRT) market cap?

Today TCRT has the market capitalization of 6.65M USD.